Further Progress in Management of CINV

Further Progress in Management of CINV

Searching for Perfection:

Not a member of My prIME? Join now for instant access.

Meeting Overview

Hear about the most up-to-date best practices for management of chemotherapy-induced nausea and vomiting (CINV) from the world’s top experts in this interactive satellite symposium. Our faculty will guide you through the current challenges for patients receiving cytotoxic therapies, as well as the best approaches available to address nausea and vomiting.

Date and Location

Friday, June 23, 2017
12.30 PM  – 2.00 PM

Palladian Ballroom
Omni Shoreham Hotel
2500 Calvert Street NW
Washington, DC 20008



Friday, June 23, 2017
12.30 PM – 2.00 PM



Washington, DC, United States



1.5 AMA PRA Category 1 Credits™



12.30 PM Welcome and introductions
Matti Aapro, MD
12.32 PM Are you up-to-date with the management of chemotherapy-induced nausea and vomiting?
Matti Aapro, MD
12.35 PM CINV: Still troubling patients after all these years
Matti Aapro, MD
12.50 PM Q & A
12.55 PM Guidelines versus individualized care for management of CINV
Mark Clemons, MD
1.10 PM Q & A
1.15 PM Getting it right the first time: Recent progress in optimizing antiemetic usage
Lee Schwartzberg, MD, FACP
1.30 PM Q & A
1.35 PM Bringing it all together: Application of current knowledge into routine clinical practices
David Warr, MD, FRCPC
1.55 PM Concluding remarks
Matti Aapro, MD
2.00 PM Adjourn


  • Matti Aapro, MDMultidisciplinary Oncology Institute
    Clinique de Genolier
    Genolier, Switzerland
  • Mark Clemons, MDThe Ottawa Hospital Cancer Centre
    University of Ottawa
    Ottawa, Ontario, Canada
  • Lee Schwartzberg, MD, FACPWest Cancer Center
    Memphis, Tennessee, United States
  • David Warr, MD, FRCPCPrincess Margaret Cancer Centre
    Toronto, Ontario, Canada

This educational activity is specifically designed to meet the needs of oncologists and other healthcare professionals involved in the treatment of patients with CINV.

After successful completion of this educational activity, participants should be able to:

  • Identify the treatment and patient risk factors for chemotherapy-induced nausea and vomiting
  • Incorporate recent changes to the clinical guidelines for CINV management into routine practice
  • Describe recent clinical trial data evaluating long acting neurokinin-1 (NK-1) receptor antagonists
  • Determine the role of a CINV risk factor toolkit to optimize individual patient management

This educational activity is supported by grants from Merck and Co, Inc. and TESARO, Inc.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

prIME Oncology designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This activity has been submitted to the Oncology Nursing Society for approval to award contact hours. ONS is accredited as an approver of continuing nursing education by the American Nurses Credentialing Center’s COA.


This activity is provided by prIME Oncology.

Sunshine Act/EFPIA Disclosure statement

prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.


Disclosure of Relevant Financial Relationships

prIME Oncology assesses the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.